more

Sage Therapeutics (SAGE)

(Real Time Quote from BATS)

$12.54 USD

+0.25 (2.03%)

Updated Jul 22, 2024 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum F VGM

Industry Rank:

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Sage Therapeutics (SAGE) Stock?

by Zacks Equity Research Published on May 27,2021

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

SAGEPositive Net Change

medical

Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study

by Zacks Equity Research Published on May 17,2021

Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.

biotechs

Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

by Zacks Equity Research Published on May 14,2021

Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)

biotechs

Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options

by Zacks Equity Research Published on May 13,2021

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

SAGEPositive Net Change

medical

Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders

by Zacks Equity Research Published on May 12,2021

Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.

biotechs

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on May 04,2021

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

SAGEPositive Net Change

Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More

by Zacks Equity Research Published on April 15,2021

The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.

biotechs

Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study

by Zacks Equity Research Published on April 13,2021

Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.

pharmaceuticals

Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options

by Zacks Equity Research Published on April 07,2021

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

SAGEPositive Net Change

medical

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research Published on February 17,2021

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAGEPositive Net Change

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

by Zacks Equity Research Published on February 01,2021

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.

biotechs

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

by Zacks Equity Research Published on December 02,2020

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies

by Zacks Equity Research Published on November 30,2020

Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.

biotechs

Sage Therapeutics (SAGE) in Focus: Stock Moves 5.1% Higher

by Zacks Equity Research Published on September 11,2020

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

medical

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on May 05,2020

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2020 results.

Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research Published on May 04,2020

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.

Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings

by Zacks Equity Research Published on May 04,2020

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.

pharmaceuticals

Cronos (CRON) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research Published on May 04,2020

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.

Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?

by Zacks Equity Research Published on May 01,2020

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 30,2020

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research Published on April 30,2020

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter 2020 results.